Physician profile
Smitty Smith
NPI 1700185519
$15,269.20
in general payments reported to CMS, 2019-2025
54 companies · $1,738 in 2025
The $1,738 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,583 · 2020: $2,160 · 2021: $2,582 · 2022: $1,882 · 2023: $1,677 · 2024: $1,646 · 2025: $1,738.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,062.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,062.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,092.81 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Boston Scientific Corporation | $1,689.76 | 2019-2025 | Ams 700 |
| Novo Nordisk INC | $1,420.29 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,388.25 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Amgen INC. | $1,243.40 | 2019-2025 | Evenity, Prolia, Prolia |
| Lilly USA, LLC | $1,110.50 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals Lp | $869.34 | 2019-2025 | Breztri, Farxiga, Fasenra |
| Takeda Pharmaceuticals U.S.A., INC. | $603.86 | 2019-2025 | Trintellix |
| Pfizer INC. | $530.80 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $436.23 | 2020-2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $370.56 | 2019-2025 | Xifaxan, Trulance, Cycloset |
| Amarin Pharma, INC. | $340.97 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $253.93 | 2019-2023 | Dificid |
| Janssen Pharmaceuticals, INC | $248.92 | 2019-2023 | Xarelto |
| Esperion Therapeutics, INC. | $241.36 | 2020-2025 | Nexletol |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Smitty Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.